system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: OBJECTIVE, METHODS, RESULTS. Meshes: Adenocarcinoma, Aged, Biomarkers, Tumor, Breast Neoplasms, Carcinoembryonic Antigen, False Negative Reactions, Humans, Likelihood Functions, Lung Neoplasms, Male, Middle Aged, Mucin-1, Pleural Effusion, Pleural Effusion, Malignant, Receptor, ErbB-2, Sensitivity and Specificity.
user
Does soluble oncoprotein 185HER-2 in pleural fluid have limited usefulness for the diagnostic evaluation of malignant effusions? Context: To investigate whether pleural levels of the soluble oncoprotein 185 HER-2 (sp185(HER-2)), individually or in combination with CEA and CA 15-3, were useful for the diagnosis of malignant effusions. Levels of CEA, CA 15-3, and sp185(HER-2) were measured in the pleural fluid from 135 malignant and 103 benign effusions. Thresholds of these tumor markers were chosen for a diagnostic specificity of >or=99%. Pleural sp185(HER-2) levels greater than 25 ng/mL were observed in 20% of breast and 10% of lung adenocarcinomas, and predicted a malignant effusion with a sensitivity of 7% and a likelihood ratio of 7.6. Combination of CEA and CA 15-3 resulted in 50% sensitivity, while adding sp185(HER-2) to this panel nonsignificantly increased sensitivity by 5% (P = 0.45). Only 1 patient with breast adenocarcinoma among 45 cytology-negative malignant effusions had sp185(HER-2) above the diagnostic cutoff point.
assistant
Measurement of pleural fluid sp185(HER-2) has poor diagnostic performance in patients with malignant effusions. Final Decision: yes